Summary

Organization name

Profile

Kanisa Pharmaceuticals, Inc. is an oncology-focused specialty pharmaceutical company employing a targeted approach to the diagnosis and treatment of cancer. Kanisa's development strategy combines new treatments for cancer with novel testing formats to stratify patients and predict likely responders to therapy.

According to Kanisa's view the future of oncology lies in defining the disease in molecular terms (i.e., genetics, genomics, proteomics) and tailoring therapies according to individual tumor and normal cell properties. This new paradigm will predetermine likely responders, assess responses earlier, and adjust treatment based on continued molecular analyses of tumors. Kanisa Pharmaceuticals expects to emerge as a leader in this paradigm shift.

The selection of likely responders for clinical trials is expected to significantly increase the response rate and therefore decrease patient enrollment requirements, shorten the clinical development and regulatory timelines, and increase the overall probability of success. Kanisa´s strategy to stratify patients will also enable physicians to better identify and respond to the unique needs of their patients. The integration of therapeutics and predictive diagnostics will advance treatment options to an individualized level of care

The company continues to seek late-stage hematology and oncology product licensing opportunities to more fully utilize its infrastructure of very experienced clinical, regulatory, and manufacturing professionals. Kanisa believes that its integrated, targeted approach will maximise treatment benefit to patients, while increasing the efficacy of new and existing drug compounds.

Kanisa is currently seeking additional oncology compounds for in-licensing. Ideal candidates would be no earlier in development than 18 months pre-IND.

Of special interest are:

• B Raf inhibitors
• CXCR4 inhibitors
• FAK inhibitors
• IGF-1R inhibitors
• JAK2 inhibitors
• PI3K inhibitors
• TIE2 inhibitors

URL

Your feedback

back